

MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDERS

Reference is made to the mandatory notification of trade in NattoPharma ASA ("NattoPharma") by primary insiders today at 9:05 AM. TG Montgomery AS ("TGM"), as a related party to NattoPharma's chairman of the Board, Frode Marc Bohan, and deputy board member, Kim Øien, have agreed to purchase additional 56,000 shares in NattoPharma at a price of NOK 38 per share, subject to the voluntarily offer (the "Offer") that Compagnie des Levures Lesaffre ("Lesaffre") is due to launch with an offer period that will commence on or prior to 19 March 2021 being completed, cf. the press release dated 15 February 2021 regarding the Offer and NattoPharma's stock exchange notice dated 25 February 2021 regarding amendments to the Offer.

TGM's pre-acceptance of the Offer covers any shares TGM owned the date TGM gave its irrevocable pre-acceptance to Lesaffre and any shares that TGM may acquire in NattoPharma prior to the completion of the Offer. This means that TGM upon completion of the acquisition of the 56,000 shares covered by this notice and the 330,360 shares reported earlier today (collectively the "Additional Shares") will transfer the Additional Shares to Lesaffre for the offer price, which currently is NOK 35.

Following the completion of the acquisition of the Additional Shares, TGM will hold 2,121,482 shares in NattoPharma, representing 10.69% of the total registered share capital and voting rights in NattoPharma, while primary insider Frode Bohan together with TGM and other related parties will control 4,032,789 shares in NattoPharma representing 20.32% of the total registered share capital and voting rights in NattoPharma, excluding 100,000 options NattoPharma that Frode Bohan has agreed to exercise and transfer to Lesaffre under the Offer.

Following the completion of the acquisition of the Additional Shares, primary insider Kim Øien together with TGM and other related parties will control 2,321,482 shares in NattoPharma representing 11.70% of the total registered share capital and voting rights in NattoPharma.